[go: up one dir, main page]

HK1251157A1 - 使用ACTRII配體陷阱治療β-地中海貧血 - Google Patents

使用ACTRII配體陷阱治療β-地中海貧血

Info

Publication number
HK1251157A1
HK1251157A1 HK18110608.3A HK18110608A HK1251157A1 HK 1251157 A1 HK1251157 A1 HK 1251157A1 HK 18110608 A HK18110608 A HK 18110608A HK 1251157 A1 HK1251157 A1 HK 1251157A1
Authority
HK
Hong Kong
Prior art keywords
thalassemia
beta
treatment
actrii ligand
ligand traps
Prior art date
Application number
HK18110608.3A
Other languages
English (en)
Inventor
M 阿蒂 肯尼士
拉亞德姆 阿伯達拉曼恩
喬普拉 拉傑什
巴克斯托姆 傑伊
Original Assignee
細胞基因公司
埃克賽勒隆製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 細胞基因公司, 埃克賽勒隆製藥公司 filed Critical 細胞基因公司
Publication of HK1251157A1 publication Critical patent/HK1251157A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18110608.3A 2015-05-13 2018-08-17 使用ACTRII配體陷阱治療β-地中海貧血 HK1251157A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562161136P 2015-05-13 2015-05-13
US201562173836P 2015-06-10 2015-06-10
US201562243457P 2015-10-19 2015-10-19
PCT/US2016/031999 WO2016183280A1 (en) 2015-05-13 2016-05-12 Treatment of beta-thalassemia using actrii ligand traps

Publications (1)

Publication Number Publication Date
HK1251157A1 true HK1251157A1 (zh) 2019-01-25

Family

ID=57248528

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110608.3A HK1251157A1 (zh) 2015-05-13 2018-08-17 使用ACTRII配體陷阱治療β-地中海貧血

Country Status (15)

Country Link
US (1) US20180125928A1 (zh)
EP (1) EP3294320A4 (zh)
JP (2) JP6976859B2 (zh)
KR (1) KR102640198B1 (zh)
CN (1) CN107847562A (zh)
AU (2) AU2016261913B2 (zh)
CA (1) CA2985777A1 (zh)
HK (1) HK1251157A1 (zh)
IL (2) IL284686B2 (zh)
JO (1) JOP20160092B1 (zh)
MY (1) MY189601A (zh)
PH (1) PH12017502079A1 (zh)
TN (1) TN2017000468A1 (zh)
TW (2) TWI814187B (zh)
WO (1) WO2016183280A1 (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018450B1 (ru) 2005-11-23 2013-08-30 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2340031B1 (en) 2008-08-14 2019-04-24 Acceleron Pharma Inc. Gdf traps for use to treat anemia
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
KR20180026795A (ko) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CA3120678A1 (en) 2012-11-02 2014-05-08 Celgene Corporaiton Activin-actrii antagonists and uses for treating bone and other disorders
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
TWI773117B (zh) 2014-12-03 2022-08-01 美商西建公司 活化素-actrii拮抗劑及治療貧血之用途
CN108350057A (zh) 2015-05-20 2018-07-31 细胞基因公司 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
EP3380121B1 (en) 2015-11-23 2023-12-20 Acceleron Pharma Inc. Actrii antagonist for use in treating eye disorders
CN116531490A (zh) 2016-07-15 2023-08-04 阿塞勒隆制药公司 用于治疗肺高血压的组合物和方法
BR112019001615A2 (pt) 2016-07-27 2019-04-30 Acceleron Pharma Inc. métodos e composições para tratar mielofibrose
CN110430890B (zh) 2016-11-10 2024-09-10 科乐斯疗法公司 激活素受体iia型变体及其使用方法
LT3638243T (lt) * 2017-06-14 2024-11-11 Celgene Corporation Su mieloproliferacine neoplazma susijusios mielofibrozės ir anemijos gydymo būdai
KR20200085832A (ko) 2017-11-09 2020-07-15 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
AU2019206634B2 (en) 2018-01-12 2024-06-27 Keros Therapeutics, Inc. Activin receptor type IIB variants and methods of use thereof
US12263205B2 (en) 2018-04-30 2025-04-01 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
EP3873501A4 (en) * 2018-10-31 2022-07-13 Celgene Corporation TREATMENT OF ANEMIA DUE TO VERY WEAK, WEAK, OR INTERMEDIATE MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH CROWN SIDEROBLASTS USING ACTIVIN-ACTRII LIGAND TRAPS
EP3999059A1 (en) 2019-07-19 2022-05-25 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (tdt)
CN112924684B (zh) * 2019-12-05 2022-07-29 中国科学院大连化学物理研究所 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒
CN115427056A (zh) * 2020-04-13 2022-12-02 细胞基因公司 使用actriib配体陷阱和菲卓替尼治疗贫血的方法
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
EP4240399A4 (en) * 2020-11-06 2024-10-09 Acceleron Pharma Inc. FORMULATIONS WITH ACTRII POLYPEPTIDE VARIANTS
US20240181007A1 (en) * 2021-01-08 2024-06-06 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
CA3205845A1 (en) 2021-01-20 2022-07-28 Francesca VINCHI Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)
WO2025003139A1 (en) 2023-06-26 2025-01-02 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247A (en) * 1845-11-01 Jordan l
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
EA202091230A3 (ru) * 2006-12-18 2021-01-29 Акселерон Фарма Инк. Антагонисты активин-actrii и их применения для повышения уровней эритроцитов
EP3363453A1 (en) * 2008-06-26 2018-08-22 Acceleron Pharma Inc. Soluble actriia as activin-actriia antagonist for use in treating anemia or bone-related disorders
EP2340031B1 (en) * 2008-08-14 2019-04-24 Acceleron Pharma Inc. Gdf traps for use to treat anemia
US20110070233A1 (en) * 2009-09-09 2011-03-24 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
EP3875104B1 (en) * 2011-10-17 2025-01-22 Acceleron Pharma Inc. Compositions for treating ineffective erythropoiesis
BR112014024358A8 (pt) * 2012-03-30 2018-01-23 Shire Human Genetic Therapies administração subcutânea de iduronato-2-sulfatase
CA2889209C (en) * 2012-10-24 2023-08-22 Celgene Corporation Biomarker for use in treating anemia
EP3527219A1 (en) * 2012-10-24 2019-08-21 Celgene Corporation Methods for treating anemia
EP2925864B1 (en) * 2012-11-27 2018-10-31 The Children's Medical Center Corporation Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction

Also Published As

Publication number Publication date
EP3294320A1 (en) 2018-03-21
CN107847562A (zh) 2018-03-27
JP2021191755A (ja) 2021-12-16
JP2018520094A (ja) 2018-07-26
IL255527B (en) 2021-07-29
WO2016183280A1 (en) 2016-11-17
TW202231294A (zh) 2022-08-16
JP6976859B2 (ja) 2021-12-08
CA2985777A1 (en) 2016-11-17
KR20180006437A (ko) 2018-01-17
PH12017502079A1 (en) 2018-06-11
AU2016261913A1 (en) 2017-11-30
IL284686B (en) 2023-01-01
AU2016261913B2 (en) 2021-08-12
IL284686A (en) 2021-08-31
IL255527A (en) 2018-01-31
AU2021258087B2 (en) 2023-04-27
TWI814187B (zh) 2023-09-01
MY189601A (en) 2022-02-18
TN2017000468A1 (en) 2019-04-12
KR102640198B1 (ko) 2024-02-23
IL284686B2 (en) 2023-05-01
TW201709927A (zh) 2017-03-16
US20180125928A1 (en) 2018-05-10
AU2021258087A1 (en) 2021-11-25
EP3294320A4 (en) 2018-12-26
JOP20160092B1 (ar) 2023-03-28
TWI762444B (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
IL284686A (en) Treatment of beta-thalassemia using ACTRII ligand traps
HUS2500001I1 (hu) Antitestkészítmények daganatkezelésre
HK1244741A1 (zh) 利用actrii配體陷阱治療心血管疾病
HK1247202A1 (zh) 用於治療癌症的化合物
IL255189A0 (en) Methods of treating cancer
HK1247823A1 (zh) 骨質疏鬆的治療
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
HUE059694T2 (hu) Készítmény rák kezelésére
DK3227262T3 (da) Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling
PL3109223T3 (pl) Mieszanina do obróbki nawozów zawierających mocznik
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3169405T3 (da) Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
BR112016015712A8 (pt) método de tratamento de doenças hepáticas.
GB201519043D0 (en) Pest traps
PL3326626T3 (pl) Środek do leczenia dermatomikozy zawierający cytrynian tripotasowy
GB201508625D0 (en) Housemite trap